Floatz logo

Lerodalcibep

Hypercholesterolemia

LIB Therapeutics LLCPhase 3Dormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
89/ 100

Competitive context

10 Active assets in the Hypercholesterolemia cohort.

Asset / SponsorPhaseRating
Ezetimibe
Punjab Institute of Cardology
Phase 4BBB
Lipitor
Punjab Institute of Cardology
Phase 4BBB
SIMVASTATIN
paresh Dandona
Phase 4BBB
PITAVASTATIN
JW Pharmaceutical
Phase 4BBB
Rosuvastatin
Sanofi
Phase 4BB

View all 36 →

Same molecule, other indications

Lerodalcibep is also rated in:

Cardiovascular Risk FactorDormant
B
Indicative ·
60 / 100
View asset →
cardiovascular disorderDormant
B
Indicative ·
57 / 100
View asset →
stroke disorderDormant
NR
Indicative ·
/ 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →